Mortality and treatment outcomes of China's national pediatric antiretroviral therapy program

Clinical Infectious Diseases

Volumn 56, Issue 5, 2013, Pages 735-744

  Zhao, Yan ^a   Li, Chunming ^a   Sun, Xin ^a   Mu, Weiwei ^a   McGoogan, Jennifer M ^a   He, Yun ^b   Cheng, Yuewu ^c   Tang, Zhirong ^d   Li, Huiqin ^e   Ni, Mingjian ^d   Ma, Ye ^a   Chen, Ray Y ^f   Liu, Zhongfu ^a   Zhang, Fujie ^a,g  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b Provincial Infectious Disease Hospital   (China)

^c Shang Cai Country Center for Disease Control and Prevention   (China)

^d Regional Center for Disease Control and Prevention   (China)

^e Provincial Center for AIDS Care   (China)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

antiretroviral therapy; China; HIV; mortality; pediatric

Indexed keywords

CD4 ANTIGEN; HEMOGLOBIN;

AGE; ANTIVIRAL THERAPY; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHILD; CHILDHOOD MORTALITY; CHINA; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; FEMALE; FOLLOW UP; HAZARD RATIO; HEALTH PROGRAM; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE TABLE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PREDICTOR VARIABLE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; CHINA; COHORT STUDIES; HIV INFECTIONS; HUMANS; INFANT; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84873651232     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis941     Document Type: Article

References (39)

1. World Health Organization. Global HIV/AIDS response. Epidemic update and health sector progress towards universal access-progress report, 2011. Available at: http://www.who.int/hiv/pub/progress-report2011/en/. Accessed 30 November 2011.
2. Judd A, Doerholt K, Tookey PA, et al. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin Infect Dis 2007; 45:918-24.
3. Brady MT, Oleske JM, Williams PL, et al. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr 2010; 53:86-94.
4. Kabue MM, Buck WC, Wanless SR, et al. Mortality and clinical outcomes in HIV-infected children on antiretroviral therapy in Malawi, Lesotho, and Swaziland. Pediatrics 2012; 130:E591-9.
5. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA 2007; 298:1888-99.
6. Callens SF, Shabani N, Lusiama J, et al. Mortality and associated factors after initiation of pediatric antiretroviral treatment in the Democratic Republic of the Congo. Pediatr Infect Dis J 2009; 28:35-40.
7. Meyers TM, Yotebieng M, Kuhn L, Moultrie H. Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa. Pediatr Infect Dis J 2011; 30:974-9.
8. Zanoni BC, Phungula T, Zanoni HM, et al. Risk factors associated with increased mortality among HIV infected children initiating antiretroviral therapy (ART) in South Africa. PLoS One 2011; 6:e22706.
9. Edmonds A, Yotebieng M, Lusiama J, et al. The effect of highly active antiretroviral therapy on the survival of HIV-infected children in a resource-deprived setting: a cohort study. PLoS Med 2011; 8: e1001044.
10. McConnell MS, Chasombat S, Siangphoe U, et al. National program scale-up and patient outcomes in a pediatric antiretroviral treatment program, Thailand, 2000-2007. J Acquir Immune Defic Syndr 2010; 54:423-9.
11. Janssens B, Raleigh B, Soeung S, et al. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics 2007; 120:e1134-40.
12. Hansudewechakul R, Sirisanthana V, Kurniati N, et al. Antiretroviral therapy outcomes of HIV-infected children in the TREAT Asia pediatric HIV observational database. J Acquir Immune Defic Syndr 2010; 55:503-9.
13. Lumbiganon P, Kariminia A, Aurpibul L, et al. Survival of HIV-infected children: a cohort study from the Asia-Pacific region. J Acquir Immune Defic Syndr 2011; 56:365-71.
14. Cardoso CA, Pinto JA, Candiani TM, Carvalho IR, Linhares RM, Goulart EM. The impact of highly active antiretroviral therapy on the survival of vertically HIV-infected children and adolescents in Belo Horizonte, Brazil. Mem Inst Oswaldo Cruz 2012; 107:532-8.
15. George E, Noel F, Bois G, et al. Antiretroviral therapy for HIV-1-infected children in Haiti. J Infect Dis 2007; 195:1411-8.
16. Ministry of Health of the People's Republic of China. 2012 China AIDS response progress report. Available at: http://wwwunaidsorg/en/dataanalysis/ knowyourresponse/countryprogressreports/2012countries/ce-CN-Narrative-Report[1] pdf2012. Accessed 31 March 2012.
17. Zhang F, Dou Z, Ma Y, et al. Five-year outcomes of the China national free antiretroviral treatment program. Ann Intern Med 2009; 151:241-51, W-52.
18. Zhang F, Dou Z, Ma Y, et al. Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infect Dis 2011; 11:516-24.
19. Zhao Y, Sun X, He Y, et al. Progress of the national pediatric free antiretroviral therapy program in China. AIDS Care 2010; 22:1182-8.
20. Zhang F, Haberer JE, Zhao Y, et al. Chinese pediatric highly active antiretroviral therapy observational cohort: a 1-year analysis of clinical, immunologic, and virologic outcomes. J Acquir Immune Defic Syndr 2007; 46:594-8.
21. Zhao Y, Mu W, Harwell J, et al. Drug resistance profiles among HIV-1 infected children experiencing delayed switch and 12-months efficacy after using second-line antiretroviral therapy: an observational cohort study in rural China. J Acquir Immune Defic Syndr 2011; 58:47-53.
22. Ma Y, Zhang F, Zhao Y, et al. Cohort profile: the Chinese national free antiretroviral treatment cohort. Int J Epidemiol 2010; 39:973-9.
23. Soh CH, Oleske JM, Brady MT, et al. Long-term effects of protease inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet 2003; 362:2045-51.
24. Li H, Ji C-Y, Zong X-N, Zhang Y-Q. Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years. Chin J Pediatr 2009; 47:487-92.
25. Resino S, Resino R, Maria Bellon J, et al. Clinical outcomes improve with highly active antiretroviral therapy in vertically HIV type-1-infected children. Clin Infect Dis 2006; 43:243-52.
26. Kekitiinwa A, Lee KJ, Walker AS, et al. Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIVinfected children in Kampala, Uganda, and the United Kingdom/Ireland. J Acquir Immune Defic Syndr 2008; 49:384-92.
27. Ciaranello AL, Chang Y, Margulis AV, et al. Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. Clin Infect Dis 2009; 49:1915-27.
28. KIDS-ART-LINC Collaboration. Low risk of death, but substantial program attrition, in pediatric HIV treatment cohorts in Sub-Saharan Africa. J Acquir Immune Defic Syndr 2008; 49:523-31.
29. Raguenaud M-E, Isaakidis P, Zachariah R, et al. Excellent outcomes among HIV+ children on ART, but unacceptably high pre-ART mortality and losses to follow-up: a cohort study from Cambodia. BMC Pediatrics 2009; 9:54.
30. Peacock-Villada E, Richardson BA, John-Stewart GC. Post-HAART outcomes in pediatric populations: comparison of resource-limited and developed countries. Pediatrics 2011; 127:e423-41.
31. Benjamin DK Jr, Miller WC, Benjamin DK, et al. A comparison of height and weight velocity as a part of the composite endpoint in pediatric HIV. AIDS 2003; 17:2331-6.
32. Sutcliffe CG, van Dijk JH, Munsanje B, et al. Weight and height z-scores improve after initiating ART among HIV-infected children in rural Zambia: a cohort study. BMC Infect Dis 2011; 11:54.
33. Kabue MM, Kekitiinwa A, Maganda A, Risser JM, Chan W, Kline MW. Growth in HIV-infected children receiving antiretroviral therapy at a pediatric infectious diseases clinic in Uganda. AIDS Patient Care STDS 2008; 22:245-51.
34. Ekouevi DK, Azondekon A, Dicko F, et al. 12-month mortality and loss-to-program in antiretroviral-treated children: the IeDEA pediatric West African database to evaluate AIDS (pWADA), 2000-2008. BMC Public Health 2011; 11:519.
35. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359:2233-44.
36. Newell ML, Coovadia H, Cortina-Borja M, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004; 364:1236-43.
37. Zhao Y, Poundstone KE, Montaner J, Zun-you W. New policies and strategies to tackle HIV/AIDS in China. Chinese Med J (Engl) 2012; 125:1331-7.
38. Geoffrey F, Bock P, MRCGP , Eley B, Mothibi E, Grimwood A. Temporal trends in baseline characteristics and treatment outcomes of children starting antiretroviral treatment: an analysis in four provinces in South Africa, 2004-2009. J Acquir Immune Defic Syndr 2011; 58: e60-7.
39. Sutcliffe CG, van Dijk JH, Bolton C, et al. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 2008; 8:477-89.